Article Text

Download PDFPDF
Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug–drug interactions (DDIs) with improved adherence and tolerability
  1. Larissa Mulka,
  2. David Annandale,
  3. Claire Richardson,
  4. Martin Fisher,
  5. Daniel Richardson
  1. Brighton and Sussex University Hospitals NHS Trust
  1. Correspondence to Dr Larissa Mulka, Department of Sexual Health and HIV, Royal Sussex County Hospital, Brighton, East Sussex BN2 5BE, UK; larissa.mulka{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Raltegravir is a well-tolerated alternative third agent used in postexposure prophylaxis (PEP).1 ,2 In a single-centre study reviewing reasons for initiation and tolerability of raltegravir-PEP, we identified patients receiving PEP between February 2010 and April 2012. All patients receiving raltegravir-PEP were matched with standard-PEP controls (tenofovir-emtricitabine with lopinavir-ritonavir (LPV/r)). Ethical approval was not required as data was collected for service evaluation.

During this period 509 courses of PEP were prescribed, 33 (6.5%) containing raltegravir. Of the 61 cases analysed 66 (92%) were prescribed PEP following sexual exposure, 54/66 (82%) were male; 47/66 (71%) men who have sex with men. Of …

View Full Text


  • Contributors All authors have contributed significantly towards data collection or analysis and interpretation All authors have contributed significantly towards drafting the work and approval of the final version and agree to be accountable for all aspects of the work. The authors wish to express their deep appreciation of the late Professor Martin Fisher who assisted in drafting and critical revision of this project.

  • Competing interests LM has received sponsorship from Gilead and Janssen to attend conferences and courses. DR has received sponsorship from Gilead and Janssen to attend conferences, and from Viiv for lecturing. DA has received sponsorship from MSD to attend a conference.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Data sharing statement The data analysed in this study was presented at the 11th International Congress on Drug Therapy in HIV Infection, Glasgow 2012 and the British Association of Sexual Health and HIV (BASHH) spring conference, Bristol 2013. The abstract presented in Glasgow can be found at